RBC Capital Maintains Outperform on Chemed, Raises Price Target to $712
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix has maintained an Outperform rating on Chemed (NYSE:CHE) and increased the price target from $604 to $712.
March 04, 2024 | 3:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained an Outperform rating on Chemed and raised the price target from $604 to $712.
The increase in price target by a reputable analyst firm like RBC Capital suggests a strong confidence in Chemed's future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100